TOFE TABLET 10 S

About

TOFE TABLET, containing Tofacitinib, is a Janus kinase (JAK) inhibitor, representing a class of targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs). It works by selectively inhibiting specific JAK enzymes (JAK1 and JAK3), which are crucial in the signaling pathways of various cytokines and growth factors involved in inflammation and immune responses. By blocking these pathways, Tofacitinib reduces the production of inflammatory mediators and modulates immune cell function, thereby decreasing inflammation and preventing joint damage in autoimmune diseases. It is used in the treatment of conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, particularly in patients who have had an inadequate response or intolerance to other therapies. Its targeted action offers a novel approach to managing chronic inflammatory conditions.

Uses

• Treatment of moderate to severe rheumatoid arthritis.
• Management of active psoriatic arthritis.
• Therapy for moderate to severe ulcerative colitis.
• Treatment of active ankylosing spondylitis.

Directions For Use

Take orally with or without food, as directed by your specialist, usually once or twice daily.

Benefits

• Reduces joint pain and swelling.
• Decreases systemic inflammation.
• Slows the progression of joint damage.
• Improves physical function and mobility.
• Effective in patients refractory to other treatments.
• Reduces fatigue associated with autoimmune diseases.

Side Effects

• Upper respiratory tract infections.
• Headache.
• Diarrhea or nausea.
• Nasopharyngitis.
• Increased cholesterol levels.
• Hypertension (high blood pressure).
• Herpes zoster (shingles).
• Anemia.
• Neutropenia (low neutrophil count).
• Serious infections (e.g., pneumonia, tuberculosis).
• Blood clots (e.g., DVT, PE).
• Malignancies (rare).

Safety Measures

• Alcohol - No specific interaction, but excessive alcohol may worsen liver function, which is a concern with this medication.
• Pregnancy - Not recommended; potential for fetal harm. Use effective contraception during and for at least 4 weeks after treatment. Consult a doctor.
• Breastfeeding - Not recommended; unknown if excreted in breast milk and potential for serious adverse effects in the infant.
• Liver - Use with caution; dose adjustment may be needed in moderate to severe impairment. Monitor liver function closely.
• Kidney - Use with caution; dose adjustment is necessary in moderate to severe impairment. Monitor kidney function closely.
• Lung - Increased risk of serious infections, including opportunistic infections and tuberculosis. Caution in patients with pre-existing lung disease.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.